about
Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulationsCoupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT ProlongationRole of cephalosporins in the era of Clostridium difficile infectionDetermination of cefuroxime in human serum or plasma by liquid chromatography with electrospray tandem mass spectrometry.Treating gonococcal infections resistant to penicillin in Bangkok: comparison of cefuroxime and spectinomycin.Simple and Robust Analysis of Cefuroxime in Human Plasma by LC-MS/MS: Application to a Bioequivalence StudyEffect of orally administered probenecid on the pharmacokinetics of cefoxitin.Clinical on-site monitoring of ß-lactam antibiotics for a personalized antibiotherapy.Cefuroxime axetil: an updated review of its use in the management of bacterial infections.The effect of Renal Failure and Dialysis on the Pharmacokinetics of CefuroximeCefuroxime in renal insufficiency: therapeutic results in various infections and pharmacokinetics including the effects of dialysis.An evaluation of cefuroxime in internal medicine.The efficacy of cefuroxime in urinary tract infections.Clinical profile of cefuroxime in sixty-four patients.Clinical evaluation of cefuroxime.Cefuroxime axetil for treatment of uncomplicated gonorrheaInfluence of serum protein binding and mode of administration on penetration of five cephalosporins into subcutaneous tissue fluid in humans.Pharmacology of Cefuroxime as the 1-acetoxyethyl ester in volunteers.Pharmacokinetics of cefuroxime in infants and children with bacterial meningitisA population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function.Cystatin C as a potential biomarker for dosing of renally excreted drugs.Cefuroxime, a beta-lactamase-resistant cephalosporin with a broad spectrum of gram-positive and -negative activity.Cefuroxime axetil (ceftin): a brief review.Beta-lactam antibiotics modulate T-cell functions and gene expression via covalent binding to cellular albumin.Pharmacokinetics of cefuroxime axetil and cefaclor: relationship of concentrations in serum to MICs for common respiratory pathogens.Pharmacokinetics of cefuroxime axetil suspension in infants and children.New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics.Pharmacokinetics and tissue concentrations of cefuroxime.Beta-lactams in sexually transmitted diseases: rationale for selection and dosing regimens.The effect of antibiotics on bone healing: current evidence.Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples.Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.Renal Drug Transporters and Drug Interactions.Irreversible effects of serum proteins on beta-lactam antibiotics.Susceptibility of cephalothin-resistant gram-negative bacilli to piperacillin, cefuroxime, and other selected antibiotics.The half-life and exposure of cefuroxime varied in newborn infants after a Caesarean section.Performance of a diffusional clearance model for beta-lactam antimicrobial agents as influenced by extravascular protein binding and interstitial fluid kinetics.Pharmacokinetics of cefuroxime in normal and impaired renal function: comparison of high-pressure liquid chromatography and microbiological assays.In vitro protein binding of cefonicid and cefuroxime in adult and neonatal sera.Pharmacokinetics of ceftizoxime in animals after parenteral dosing.
P2860
Q27020967-2A698328-F963-4F6F-A398-A4DD884E753FQ27231482-CD4DC5ED-34FF-471F-BC6B-CF2BAF40C302Q28078261-D65E450A-2342-4DA7-BDAB-883A52D4DC07Q33200554-E971E4F8-32E6-4C58-A053-1FB75899E9D3Q33582915-7E391FE0-1657-4BC1-9E5B-F0811B5AE11DQ33597790-5890AFA2-B5D1-46B4-A984-54BA4548681CQ33728926-E3DAEBC9-AD2D-4D19-A3CF-835FA5D296ECQ33784516-D2DAE083-4D70-4510-A11B-0D5A9D142953Q34370476-EADCEFD3-6433-481A-AAFF-6CD899F644A1Q34982369-01A4F59F-635D-4D15-95CB-ED2436BB6838Q34982401-A54A8675-17BA-46EC-9C2A-7DA3E35437FEQ34982413-BF4B408B-3E17-4ADA-997F-63056B8C166EQ34982436-4727CEF5-6004-4AA8-A049-EC05CCF04510Q34982462-2D65DB21-2EB7-4244-8646-971E04AE98A2Q34982482-AB010CD1-7F24-4FD8-8F36-915AA3774B10Q35651955-B1C3DE3E-D97B-4D93-B432-B7ECEFEE7675Q35672660-1349A252-B834-4AA6-8062-FBD0506963BEQ35756272-6818ECC6-6841-463D-8736-D0AFF9C03A55Q35761827-E22163B4-A101-4AA3-9BF8-A623458E5A5FQ35827765-AC54AA2C-3746-46BF-97FD-92A3ED34FABBQ35846113-5A51BBAD-2A96-4C7B-80BA-0EE6008E05A1Q36468807-D85E0B17-E0D7-4880-8149-3CB5BC1B2065Q36625270-BF13FC1C-F51D-42E5-A23A-B2CD7A9C8011Q36637602-A357A31A-5433-4D49-982C-F59DF2D69544Q36754904-B8AE8DBA-0AC6-46E1-88D7-2F65747B1CDAQ36755698-6D6AA138-5795-4BE7-85E6-8C8C78B9FBD7Q37274639-E77ADF47-8726-4035-A26C-7F857F62B0A6Q37782711-3B176552-62E4-4C90-85CA-20588063D03FQ37905141-B34E9897-EFD5-4EF5-970F-47A59B866471Q37913390-976894CC-B13C-40E8-9895-731842F72A6AQ38369608-0850830E-5E38-45A3-B883-FE0890E548C6Q38846048-8E9A6A27-938B-4FC7-9822-8C5984D1E1C2Q39140289-AD51AEB2-9F1F-417B-BC13-F101D9FC1BF3Q39198998-F619BD65-18AF-45EB-8C3A-8007E4BD3F5AQ39725504-E3138110-796C-4A93-87DC-684FAED1B5C3Q39725577-91B6459D-6C54-4399-A169-1AFA56864336Q39850258-7CF01FF7-8C39-4613-9E47-3800021356D2Q39854727-E0D2B276-A4BD-4715-AECA-F1D16AAE30D7Q39866199-E145FC38-6D61-434B-9208-FEFDA1FA2400Q40281398-388B8B10-FC6C-4105-BE9D-58D8C2998894
P2860
description
1976 nî lūn-bûn
@nan
1976年の論文
@ja
1976年論文
@yue
1976年論文
@zh-hant
1976年論文
@zh-hk
1976年論文
@zh-mo
1976年論文
@zh-tw
1976年论文
@wuu
1976年论文
@zh
1976年论文
@zh-cn
name
Cefuroxime: human pharmacokinetics..
@en
type
label
Cefuroxime: human pharmacokinetics..
@en
prefLabel
Cefuroxime: human pharmacokinetics..
@en
P2860
P356
P1476
Cefuroxime: human pharmacokinetics..
@en
P2093
P2860
P304
P356
10.1128/AAC.9.5.741
P407
P577
1976-05-01T00:00:00Z